VERIstic makes blood sample collection quick, simple and comfortable for patients and clinicians. Credit: Rhinostics, Inc / Business Wire.

Rhinostics has launched its new device, VERIstic, which focuses on the collection of small volume blood and is designed for use in at-home and clinician-assisted collection processes.

It serves as a high-throughput replacement for the detection of proteins, antibodies and hormones, as well as other applications that use finger prick collection, such as testing for sexually transmitted infections (STIs), genetic testing, dried blood spot (DBS) cards and clinical trials.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The VERIstic collection device is claimed to be the first of its kind to combine new capillary blood collection with an integrated, automation-ready cap.

The design of the patent-pending three-sided capillary device combines tried-and-true wicking action for the collection of 50µL of blood with automated, walkaway processing that saves time and money.

The tube is then screwed into a matching transport tube to be sent to the laboratory.

See Also:

The new device makes the collection of blood samples quick, simple and comfortable for patients and clinicians.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Rhinostics president and CEO Cheri Walker said: “Finally, patients and clinicians can be assured of comfortable metered blood collection, where the clear capillary allows the collector to monitor collection and laboratories gain consistent blood collection combined with cost and time-saving efficiencies during processing through automated decapping and robotic sample processing.”

The company noted that VERIstic is suitable for various applications, including wound care, blood monitoring, clinical trials, other small volume body fluids, and many home- or clinic-based sample collection needs.

In May, Rhinostics and Nexus Medical Labs received emergency use authorisation (EUA) from the US Food and Drug Administration (FDA) for a molecular SARS-CoV-2 test.